Facilities
- Home
- Facilities
Smart. Secure. Scientific. Scalable
Trusted Platform for Progress
Our Success Stories
Our Manufacturing Footprint
Manufacturing Units:
HAB Pharma operates multiple manufacturing facilities across key locations in India, with an expanding manufacturing infrastructure comprising multiple production blocks and a workforce of 600+ professionals. Together, these facilities provide an integrated platform for the manufacture of a diverse range of pharmaceutical formulations.
Dosage forms handled:
Across its manufacturing network, HAB Pharma produces a broad range of dosage forms, including tablets, capsules, injections, drops, ointments, and other external preparations, along with specialised formats such as oral jellies and aerosols. This diverse manufacturing base enables the company to cater to varied product requirements across oral solids, sterile injectables, topical, and liquid formulations.
Total production capacity:
The combined production capacity of the network is more than 4.4 billion units annually, comprising around 2,000+ million tablets, 1,850+ million capsules, 510+ million units of ointment and external preparations, 22+ million drops, and 7+ million injections.
01
Unit 1, Vasai, Mumbai
Located in Vasai, Mumbai, this established HAB Pharma manufacturing facility comprises a dedicated production block with approximately 1,200 square metres of built-up area across about 500 square metres of land. The facility is supported by a workforce of 100+ professionals and operates as an efficiently integrated manufacturing unit focused on oral solid dosage forms, with infrastructure designed to support consistent quality and reliable production.
Capabilities
Dosage forms: Tablets and capsules. Production processes include granulation, compression, coating, capsule filling, and blending operations such as drum, octagonal, and dry blending. Packaging capabilities include blister packing across online and offline lines, supporting flexibility in packaging formats and batch sizes.
Capacity
Annual capacity includes 670+ million tablets and 225+ million capsules. Output from this facility is supplied to South Asia, Africa, and Southeast Asia.
Certifications
02
Unit 2, Selaqui, Dehradun
Located in Selaqui, Uttarakhand, this HAB Pharma facility spans over 10,000 square metres across two dedicated production blocks, supported by a combination of owned and leased land. The facility is supported by a workforce of 250+ professionals and integrates multiple dosage forms and manufacturing capabilities within a single location, providing a versatile and scalable platform for pharmaceutical production.
Capabilities
Dosage forms: Tablets, capsules, drops, and ointments/external preparations, including oral jelly and aerosol formats. Production processes include granulation, compression, coating, capsule filling, formulation manufacturing, eye drop filling, tube filling, and aerosol filling. Packaging capabilities include blister packing (online and offline), pouch sealing, and packaging for tube and aerosol products.
Capacity
Annual capacity includes 832+ million capsules, 582+ million tablets, 450+ million units of ointment and external preparations (including oral jelly and aerosols), and 22+ million drops. This unit serves export markets across Latin America, Southeast Asia, South Asia, the Middle East, and Africa.
Certifications
03
Unit 3, Selaqui, Dehradun
Located within HAB Pharma’s Selaqui campus in Dehradun, this facility spans over 10,000 square metres across multiple manufacturing sections, comprising a combination of owned and leased premises. The facility is supported by a workforce of 200+ professionals and includes a dedicated sterile manufacturing suite, enabling in-house production of injectable formulations alongside other pharmaceutical manufacturing capabilities.
Capabilities
Dosage forms: Tablets, capsules, injections, and ointments/external preparations, including aerosol formats. Production processes:
- Section I Beta
- Section II Cepha
- Section III General
Capacity
Annual capacity includes 798+ million capsules, 757+ million tablets, 65+ million units of ointment and external preparations, and 7+ million injections. This unit supplies products to the Middle East, South Asia, Southeast Asia, and Africa.
Certifications
Integrated Manufacturing Platform
HAB Pharma’s three manufacturing units collectively support the production of oral solids, sterile injectables, and topical and liquid formulations, creating a diverse manufacturing platform across six production blocks. The network covers key processes including granulation, compression, coating, capsule filling, formulation manufacturing, liquid filling, and blister packing, with capabilities distributed across facilities based on dosage form and production requirements.
Across the three units, HAB Pharma has an annual production capacity of approximately 4.4+ billion units, comprising around 2,000+ million tablets, 1,850+ million capsules, 510+ million units of ointment and external preparations, 22+ million drops, and 7+ million injections. Together, these capabilities provide an integrated manufacturing base serving both domestic and international markets.
Quality & Compliance
01
Quality control systems
All three facilities operate under a shared quality management framework rather than site-specific standards. In-process checks are built into each stage of production, granulation, compression, coating and filling, so deviations are caught at the point they occur rather than only at final release. Batch release itself is gated on documented inspection at every one of those stages, which keeps the release decision consistent regardless of which block or unit produced the batch.
02
Regulatory compliance
All three units hold WHO-GMP and ISO 9001:2015 status, the baseline regulatory position across the network. Unit 2 is additionally pursuing CE marking, specifically for its nasal, ophthalmic, medical device and wound dressing lines, which would extend the network's regulatory reach into markets that require CE-marked medical devices alongside conventional pharmaceutical registrations. No USFDA or EU-GMP certification currently applies to the facilities described here.
03
Audits & certifications
Running a shared quality standard across three units, rather than a separate standard per site, has let HAB Pharma support repeat regulatory and customer audits without needing site-specific rework each time an auditor visits a different block. That consistency underpins the group's export reach into South Asia, Africa, Southeast Asia, Latin America and the Middle East, where customers and regulators alike expect the same documented process discipline whichever HAB Pharma facility a given batch was produced at.
Talk to the Facilities Team
Whether you’re evaluating HAB Pharma for contract manufacturing, checking available capacity for a specific dosage form, confirming certification for a regulated market, or simply want to see a plant in person, the facilities team can walk you through site-specific detail that isn’t captured in this overview, current line utilisation, lead times, and product-fit for your formulation.
- A-301, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel (West), Mumbai – 400013.
- info@habpharma.in
- 022-66261400
Quick Links
- About Us
- Sales & Distribution
- Contract Manufacturing
- Press and News
- Export
- Investor Relation